Counselors in Sturgis, SD - Medicare Status, Address, Contact

21 Counselors found. Showing 21 - 21

Kathy Jean White, LAC OR NCAC I
Counselor - Addiction (Substance Use Disorder)
Medicare: Not Enrolled in Medicare
Practice Location: 1238 Main St Ste 4, Sturgis, SD 57785
Phone: 605-720-8090 Fax: 605-720-8090

News Archive

New maturation inhibitor drugs may help solve HIV treatment conundrum

Since AIDS was first recognized in 1981, significant advances have been made in developing an effective arsenal of drugs to manage the disease and extend patients' lives.

TP53 gene variant may lead to early onset of brain tumor

People with a particular gene variant may be more likely to develop brain tumors, and at an earlier age, than people without the gene, according to a study published in the January 27, 2009, print issue of Neurology, the medical journal of the American Academy of Neurology.

Accera commences clinical efficacy trial of AC-1204 for mild-to-moderate Alzheimer's disease

Accera, Inc., a privately-held, commercial-stage, healthcare company focused on the discovery and development of innovative clinical applications to address acute and chronic neurodegenerative diseases, announced today the initiation of a clinical efficacy trial examining the effects of AC-1204 in patients with mild-to-moderate Alzheimer's disease (AD).

Recommendation against routine PSA measurement relies too heavily on randomized trial data

Do the results of recent randomized trials justify the recent U.S. recommendation against yearly measurement of prostate-specific antigen (PSA) as a screening test for prostate cancer? That's the topic of debate in a special "point/counterpoint" section in the April issue of Medical Care.

Aeterna Zentaris reaches SPA agreement with FDA for AEZS-108 Phase 3 trial in endometrial cancer

Aeterna Zentaris Inc. today announced that it has reached an agreement with the U.S. Food and Drug Administration ("FDA") on a Special Protocol Assessment ("SPA") for an upcoming Phase 3 registration trial in endometrial cancer with its doxorubicin peptide conjugate, AEZS-108. The SPA agreement states that the proposed trial protocol design, clinical endpoints and planned analyses are acceptable to the FDA to support a regulatory submission.

Counselors in Sturgis, SD Accepting Medicare